Transcenta partners with WuXi Biologics to commercialise bioprocessing technology

Transcenta Therapeutics, a global clinical-stage biopharmaceutical company, has partnered with WuXi Biologics to commercialize its Highly Intensified Continuous Bioprocessing (HiCB) technology. The collaboration, signed between Transcenta and its subsidiary HJB, grants WuXi Biologics a non-exclusive license to utilize Transcenta's HiCB platform and ExcelPro cell culture media.

Under the agreement, Transcenta will grant WuXi Biologics an upfront payment of RMB 10 million. Further milestone payments will be made upon the fulfillment of specific conditions. This partnership will enable WuXi Biologics to take on the role of Transcenta's strategic ally for CMC development and the support of molecules throughout Transcenta's development pipeline.

The HiCB platform, developed by Transcenta, integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification. This innovative approach enhances productivity by significantly reducing the cost of goods and lowering capital investment requirements. By maintaining superior product quality through shorter residence time and optimized culture conditions, HiCB also offers a solution for improving recovery yield and product quality, particularly for complex biologics.

This collaboration reflects Transcenta's ongoing commitment to advancing its HiCB technology platform and expanding its applications to tackle CMC challenges associated with complex biologic molecules. The partnership further provides a flexible approach to rapidly expanding production capacity, aligning with Transcenta's goal of unlocking the commercial value of the HiCB platform through external licensing and industry collaborations.